Synthesis and Evaluation of Zwitterionic Carbohydrate Immunostimulants

 描述（由申请人提供）：尽管使用疫苗对抗传染病极大地改善了人类健康，但它们的免疫原性差，需要多次接种才能保护。因此，疫苗与佐剂共同施用以增强免疫力。在过去的几十年里，已经开发了许多种类的疫苗佐剂，并显示出所需的免疫应答。不幸的是，只有少数佐剂被认为是足够有效的，并在临床上适用于人类。明矾a 氢氧化铝和磷酸盐的混合物仍然是主要的佐剂，具有广泛的安全记录，被批准用于人类疫苗接种。 在努力发现新的佐剂，一种不寻常的碳水化合物，两性离子多糖（ZPS），在其重复单元中含有负电荷和正电荷基序，被发现激活CD 4 + T细胞依赖性免疫应答和调节宿主细胞因子对细菌感染的应答。当与抗原破伤风类毒素共同施用时，ZPS增加特异性抗体等级，说明它们在体内充当潜在疫苗佐剂的能力。最佳表征的ZPS之一是两性离子多糖PS A1，其分离自荚膜脆弱拟杆菌。研究表明，由PSA 1与肿瘤相关粘蛋白抗原TN的缀合产生的糖缀合物产生对TN半抗原具有特异性和选择性的高滴度抗体。 尽管PSA 1作为潜在佐剂的前景，但从天然来源获得它是一个复杂的提取和纯化过程，导致产生微小的、相对不纯的量，并可能改变其结构。由于FDA对用于人类的疫苗佐剂的纯度和质量有严格的规定，因此必须开发合成来源以使PS A1用作临床相关佐剂。本提案的主要目标是利用我们最近开发的镍催化α-糖基化方法，通过化学合成具有确定重复单元的天然和非天然PS A1寡糖来应对这些挑战。这项拟议的努力将提供高纯度的定义的PS A1分子，而没有批次间的变化，并提供研究其作为佐剂的作用和探索结构关系活性（SAR）研究的工具。1

 DESCRIPTION (provided by applicant): Although the use of vaccines to combat infectious diseases has greatly improved human health, they are poorly immunogenic and requires multiple doses for protection. As such, vaccines are co-administered with an adjuvant to enhance immunity. Numerous classes of vaccine adjuvants have been developed and showed the desired immune response over the past several decades. Unfortunately, only a few adjuvants are considered to be sufficiently potent and clinically liable for use in humans. Alum, a mixture of aluminum hydroxide and phosphate salts, remains the dominant adjuvant with extensive safety record approved for use in human vaccination. In efforts to discover new adjuvants, an unusual class of carbohydrates, zwitterionic polysaccharides (ZPSs), containing both negative and positive charge motifs in their repeating units, were found to activate CD4+ T-cell-dependent immune responses and modulate host cytokine responses to bacterial infection. ZPSs when co-administered with antigen tetanus toxoid increase the specific antibody tier, illustrating their capacity to serve as potential vaccine adjuvants in vivo. One of the best characterized ZPSs is zwitterionic polysaccharide PS A1, isolated from capsular Bacteroides fragilis. Studies showed that glycoconjugates, generated from conjugation of PS A1 to tumor-associated mucin antigen TN, elicits high titer antibodies that are specific and selective for the TN hapten. Despite the promise of PS A1 as a potential adjuvant, obtaining it from natural sources is a complicated process of extraction and purification that results in the production of minute, relatively impure quantities and could alter its structure. Since FDA has strict regulation regarding the purity and quality of vaccine adjuvants for use in humans, a synthetic source must be developed for PS A1 to be utilized as a clinically relevant adjuvant. The main goal of this proposal will address these challenges through the chemical synthesis of natural and non-natural PS A1 oligosaccharides with defined repeating units utilizing our recently developed nickel-catalyzed α-glycosylation methodologies. This proposed effort will deliver defined PS A1 molecules in high purity without batch-to-batch variation and provide tools for studying their roles as adjuvants and exploring structure-relationship activity (SAR) studies. 1